Caribou Biosciences’ (CRBU) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Caribou Biosciences (NASDAQ:CRBU) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $9.00 price objective on the stock. HC Wainwright also issued estimates for Caribou Biosciences’ Q1 2025 earnings at ($0.43) EPS, Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.94) EPS.

Other research analysts also recently issued reports about the stock. Bank of America dropped their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Citigroup lowered their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Stock Performance

Caribou Biosciences stock opened at $1.04 on Wednesday. Caribou Biosciences has a 1 year low of $0.95 and a 1 year high of $5.62. The firm’s 50 day moving average price is $1.29 and its two-hundred day moving average price is $1.74. The firm has a market cap of $96.73 million, a price-to-earnings ratio of -0.63 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.08 million for the quarter, compared to analyst estimates of $2.11 million. As a group, equities analysts predict that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRBU. Public Employees Retirement System of Ohio acquired a new stake in shares of Caribou Biosciences during the 4th quarter valued at $222,000. Two Sigma Investments LP boosted its position in Caribou Biosciences by 23.7% during the fourth quarter. Two Sigma Investments LP now owns 1,118,696 shares of the company’s stock valued at $1,779,000 after purchasing an additional 214,239 shares during the last quarter. Two Sigma Advisers LP grew its stake in Caribou Biosciences by 39.5% in the fourth quarter. Two Sigma Advisers LP now owns 1,470,700 shares of the company’s stock valued at $2,338,000 after purchasing an additional 416,600 shares in the last quarter. Nuveen Asset Management LLC increased its position in Caribou Biosciences by 23.6% in the 4th quarter. Nuveen Asset Management LLC now owns 330,831 shares of the company’s stock worth $526,000 after purchasing an additional 63,096 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Caribou Biosciences by 52.9% during the 4th quarter. Millennium Management LLC now owns 859,825 shares of the company’s stock worth $1,367,000 after purchasing an additional 297,351 shares in the last quarter. 77.51% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.